Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SNOA 
Sonoma Pharmaceuticals Inc (SNOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SNOA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.54% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.89M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 3125830 | Beta 1.56 | 52 Weeks Range 1.90 - 9.37 | Updated Date 04/1/2025 |
52 Weeks Range 1.90 - 9.37 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.82% | Operating Margin (TTM) -28.93% |
Management Effectiveness
Return on Assets (TTM) -19.72% | Return on Equity (TTM) -64.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1578475 | Price to Sales(TTM) 0.28 |
Enterprise Value -1578475 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 1615760 | Shares Floating 1594825 |
Shares Outstanding 1615760 | Shares Floating 1594825 | ||
Percent Insiders 1.25 | Percent Institutions 1.26 |
Analyst Ratings
Rating 5 | Target Price 19.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sonoma Pharmaceuticals Inc
Company Overview
History and Background
Sonoma Pharmaceuticals, Inc. (SNOA) was founded in 1997 as Oculus Innovative Sciences, Inc. and later rebranded. It focuses on developing and marketing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, dermatology, and eye care.
Core Business Areas
- Dermatology: Products for acne treatment, eczema, and other skin conditions.
- Wound Care: Products used for wound cleansing, debridement, and infection prevention.
- Eye Care: Products for treating blepharitis, dry eye, and other ocular surface diseases.
- International Sales: Distribution of products through partners in various international markets.
Leadership and Structure
The leadership team consists of executive officers with experience in pharmaceuticals and medical devices. The company has a board of directors that oversees strategic direction.
Top Products and Market Share
Key Offerings
- MicrocynRx: A prescription-strength HOCl solution used for wound care and dermatology. Market share data is not readily available. Competitors include other wound care and antiseptic products such as those from Smith & Nephew and 3M.
- OCuSOFT HypoChlor: An over-the-counter HOCl solution for eyelid hygiene. Market share data is not readily available. Competitors include other eyelid cleansers from companies like Bruder Healthcare.
- Alevicyn: Indicated for Atopic Dermatitis and market share not readily available. Competitors include topical steroid products from brands such as Cortizone 10.
Market Dynamics
Industry Overview
The market for wound care, dermatology, and eye care products is large and competitive, with increasing demand driven by aging populations, chronic diseases, and growing awareness of skin and eye health.
Positioning
Sonoma Pharmaceuticals focuses on developing and marketing HOCl-based products, which are considered safe and effective alternatives to traditional treatments. Their competitive advantage lies in their proprietary HOCl formulations.
Total Addressable Market (TAM)
The TAM for wound care, dermatology, and eye care is estimated to be billions of dollars. Sonoma is positioned to capture a portion of this TAM through its HOCl technology, focusing on specific niche applications within these broad categories.
Upturn SWOT Analysis
Strengths
- Proprietary HOCl technology
- Established product portfolio
- Distribution network
- Strong safety profile of products
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on distribution partners
- Small market capitalization
- Fluctuating revenue
Opportunities
- Expanding into new markets and applications
- Partnering with larger pharmaceutical companies
- Developing new HOCl-based products
- Increasing awareness of HOCl benefits
Threats
- Competition from established pharmaceutical companies
- Regulatory changes
- Pricing pressure
- Generic alternatives
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABT
- BAYRY
- SNY
Competitive Landscape
Sonoma Pharmaceuticals faces intense competition from larger pharmaceutical companies with greater resources and established market presence. It aims to differentiate itself through its HOCl technology and focus on niche markets.
Major Acquisitions
Intraderm Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 5.3
- Strategic Rationale: Acquisition broadened Sonoma's product portfolio and expanded its presence in dermatology. (Source: Sonoma Pharmaceuticals, Inc. (SNOA) SEC Filing 8-K, August 11, 2023)
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to market conditions and product adoption rates.
Future Projections: Future growth depends on successful product launches, market penetration, and strategic partnerships. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding international distribution, developing new product formulations, and focusing on direct-to-consumer sales.
Summary
Sonoma Pharmaceuticals is a small company with a proprietary HOCl technology, but faces significant competition from larger players. While its products show promise in various applications, its limited financial resources and inconsistent historical growth present challenges. Successful expansion, strategic partnerships, and effective marketing are crucial for future success. Sonoma Pharmaceuticals must navigate a competitive landscape, focusing on its strengths to achieve sustainable growth.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
PFE
Pfizer Inc
PFE
Pfizer Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q, 8-K)
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonoma Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2007-01-25 | CEO, President & Director Ms. Amy M. Trombly J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 10 | Website https://sonomapharma.com |
Full time employees 10 | Website https://sonomapharma.com | ||
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.